To determine the capability of selected anti-apoptotic BCL-2 family members as therapeutic targets in BCP-ALL, we used inhibitors selectively antagonizing BCL-2 (venetoclax), MCL-1 (S63845), and BCL-XL (A-1331852). The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.